Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
21 September 2020
MESSAGE FROM THE RECTOR AND VICE-CHANCELLOR: UPDATE ON DEVELOPMENTS AT THE UFS

I hope you are well, healthy, and safe. I have experienced an overwhelming sense of commitment from staff and students across the university to make a success of the 2020 academic year. Thank you for working together towards this common goal.

Currently, we have a significant number of students back on the campuses in line with the university’s reintegration plan, and others are continuing with online learning. On 16 September 2020, President Cyril Ramaphosa announced that the country will move to alert Level 1 as from midnight on Sunday 20 September 2020. During Level 1 of the national lockdown, we will continue to return staff and students in a structured and phased approach according to the university’s reintegration plan. However, we are still unable to return all our students to the campuses, as we have to adhere to physical distancing and hygiene measures and also have to take into account the capacity of the lecture venues on the campuses, but most specifically the residences.

Please note that you will be informed by your faculty if you are required to return to campus during Level 1. If you have NOT been contacted, you will be supported through remote multimodal teaching, learning, and assessment until you are informed by your faculty that you can return to campus.

Data shows that most of you have adapted well to the blended learning modes – I find it admirable and inspiring. Rest assured that your lecturers are continuing to work hard to deliver a quality teaching and learning experience. Please use the #LearnOn material as a guide to plan for the second semester and engage with your lecturers on academic problems or consult with your faculty structures to find suitable solutions.

The university is aware that international students who have been residing outside of the country during Levels 5 and 4, may return to campus during Level 1; we will communicate with these students in due course.

I am confident that you are focused and committed to completing the second semester. We have prepared a safe environment for students who are returning to campus during Level 1. Sufficient hygiene measures are in place, as well as re-configurations to ensure physical distancing. The wearing of masks, physical distancing, and hand sanitising remain compulsory on all the campuses.

During Level 1, campus access will remain restricted – only those with campus access permits will be allowed to enter. Space in our residences remains limited due to physical distancing and residence students must comply with the protocols in their respective residences. See the Return to campus of students_Level 1 of national lockdown document for more information.

Although our country will be on Level 1 of the national lockdown, it is still extremely important that you remain vigilant and take ownership of your health and look out for the health of those around you. Ultimately, your health is your responsibility. Please do not let your guard down and adhere to the protocols and regulations – for your own safety, and for the safety of others.

It is also important to keep your mental health in check – make use of the #WellbeingWarriors campaign from our Department of Student Counselling and Development, which is aimed at encouraging health and well-being among students. Visit the COVID-19 website for comprehensive information and updates.

Although the infection rate in our country is decreasing, remember that the COVID-19 pandemic is still testing every aspect of society; we must not underestimate the impact that the pandemic still has on local and global communities. Take care of yourselves and those around you and comply with the national guidelines and regulations.

I wish you all the best with your studies.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept